Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma

Lymphoma

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

Blood Cancer J

Ong SY, Chen L, Manzano JM, Merryman R, Shah H, Stuver R, Desai SH, LaCasce A, Falade A, Baron K, Ganesan N, Chang T, Durani U, Othman T, Armand P, Mei M, Moskowitz AJ, Herrera AF

doi: 10.1038/s41408-026-01547-2

Lymphoma

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

Haematologica

Basile G, Neuville A, Martineau D, Delapierre B, Dubois S, Noel R, Durot E, Caillet A, Labouré G, Laribi K, Gros FX, Bernard S, Mineur A, Borel C, Chartier L, Damaj G, Bouabdallah K, Galtier J

doi: 10.3324/haematol.2025.300289

Lymphoma

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leuk Lymphoma

Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL

doi: 10.1080/10428194.2025.2525982

Lymphoma

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

J Clin Oncol

Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J

doi: 10.1200/JCO-25-01957

Leukemia

Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation

Br J Haematol

Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, Tischer J, Sica S, Gülbas Z, Socié G, Blaise D, Pioltelli P, Ozdogu H, Vydra J, Ciceri F, Nagler A, Mohty M

doi: 10.1111/bjh.70101

Lymphoma

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Br J Haematol

Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S, ATL working groups of the Japanese Society for Transplantation and Cellular Therapy

doi: 10.1111/bjh.70631

ASH 2025

Leukemia

ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3^mut AML

Lymphoma

Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis

Haematologica

Tharmaseelan H, Sgonina LM, Bühnen I, Schnetzke U, Meißner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Bröckelmann PJ, Kobe C, Borchmann P, Von Tresckow B

doi: 10.3324/haematol.2025.288996

Lymphoma

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

J Clin Oncol

Leonard JP, Trněný M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG, AUGMENT Trial Investigators

doi: 10.1200/JCO-25-01770

Related content

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3mut AML

Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3^mut AML